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Abstract
Pheochromocytomas (PCC) are catecholamine-producing tumors arising from the adrenal
medulla that occur either sporadically or in the context of hereditary cancer syndromes, such as
multiple endocrine neoplasia type 2 (MEN2), von Hippel-Lindau disease (VHL), neurofibromatosis
type 1, and the PCC-paraganglioma syndrome. Conventional comparative genomic hybridization
studies have shown loss of 1p and 3q in the majority of sporadic and MEN2-related PCC, and 3p
and 11p loss in VHL-related PCC. The development of a submegabase tiling resolution
array enabled us to perform a genome-wide high-resolution analysis of 36 sporadic benign PCC.
The results show that there are two distinct patterns of abnormalities in these sporadic PCC, one
consisting of loss of 1p with or without concomitant 3q loss in 20/36 cases (56%), the other
characterized by loss of 3p with or without concomitant 11p loss in 11/36 (31%). In addition, we
found loss of chromosome 22q at high frequency (35%), as well as the novel finding of high
frequency chromosome 21q loss (21%). We conclude that there appear to be two subgroups of
benign sporadic PCC, one of which has a pattern of chromosomal abnormalities that is
comparable with PCC from patients with MEN2 and the other that is comparable with the PCC that
arise in patients with VHL disease. In addition, genes on 21q and 22q might play a more important
role in PCC pathogenesis than had been assumed thus far.
Endocrine-Related Cancer (2009) 16 505–513
Introduction
Pheochromocytomas (PCC) are rare neuro-endocrine
tumors arising from the adrenal medulla. Similar tumors
arise from extra-adrenal chromaffin tissues, and are now
referred to as sympathetic paragangliomas (PGLs;
Baguet et al. 2004). These tumors produce catechol-
amines, causing paroxysmal or sustained hypertension in
the majority of patients. The elevated blood pressure can
cause myocardial and cerebral infarctions, leading to
morbidity andmortality. In up to 25%ofPCC, the tumors
occur in the context of four hereditary tumor syndromes,
including multiple endocrine neoplasia type 2 (MEN2),
von Hippel-Lindau disease (VHL), the PCC–PGL
syndrome, and neurofibromatosis type 1 (NF1;Neumann
et al. 2002). Patients with MEN2 have mutations of the
RET oncogene located at 10q11.21, the VHL tumor
suppressor gene is located on 3p25.3, the SDHD gene in
PGL–PCC patients is located on 11q23.1, and the related
SDHB gene, also involved in the PCC–PGL syndrome is
located on 1p36.13. Finally, the NF1 gene is located on
17q11.2. In the remaining 75% of sporadic PCC somatic
mutations of these five genes play a minor role, and the
pathogenesis of these tumors is largely unknown.
Both syndrome-related PCC and sporadic PCC have
been analyzed by comparative genomic hybridization
(CGH). Interestingly, PCC from MEN2 patients, NF1
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patients, and the majority of sporadic PCC show similar
genomic aberrations with a characteristic loss of 1p and
3q (Dannenberg et al. 2000, Edstrom et al. 2000,Cascon
et al. 2005). VHL-related PCC, however, show distinct
genetic aberrations consisting of loss of chromosomes 3
and 11 (Lui et al. 2002, Hering et al. 2006).
With the introduction of high-resolution array-CGH,
it has become technically feasible to study small
(submegabase) chromosomal deletions and gains that
escaped detection by conventional CGH due to the low
resolution. This technique has facilitated the analysis
of chromosomes 21 and 22 that were difficult to
analyze in conventional CGH. Recently, copy number
imbalances affecting chromosome 22 were confirmed
by submegabase array-CGH in 44% (29/66) of PCC
analyzed, a percentage that had not been described in
conventional CGH (Jarbo et al. 2006). In addition, the
tiling order of bacterial artificial chromosome (BAC)
clones also has the advantage to rule out mismapped
clones, and gives precise breakpoint information.
A similar array-CGH analysis has been performed on
chromosome arm 1p, with 24 samples from hereditary
and sporadic PCC, in which breakpoints of chromo-
some 1p could be identified precisely. These studies
illustrate important differences between conventional
and array-CGH (Aarts et al. 2006). To further clarify
the pathogenesis of sporadic PCC, we analyzed 36
sporadic benign PCC using a tiling array consisting of
32 433 BAC clones.
Materials and methods
Patients and tumor samples
A series of 40 benign PCC of 40 patients was obtained
from the archives of the Departments of Pathology of
the Erasmus MC-University Medical Center Rotter-
dam, Maastricht University, Academic Medical
Center Amsterdam, University Medical Center St
Radboud Nijmegen, and University Medical Center
Utrecht, the Netherlands and stored at the Erasmus
MC tissue bank. Patients with each of the following
characteristics were excluded from this study: positive
family history of an endocrine hereditary cancer
syndrome, evidence of NF1, multiple PCC, and/or
PGL or the presence of germline mutations. In
addition, none of the patients had other tumors related
to MEN2, VHL or the PCC–PGL syndrome. After this
selection, the study was performed with 36 benign
truly sporadic tumors of 36 patients, of which two
patients with sympathetic PGL. The cohort consisted
of 17 females and 19 males. The mean age was 49
years (range 9–76), with an average follow-up of 4.4
years (nZ25 patients, 11 patients were lost to follow-
up). None of the patients had evidence of metastatic or
recurrent disease during follow-up, and therefore are
considered benign. The mean diameter of the tumors
was 5.6 cm (range 2.5–18). Most tumors produced
mainly norepinephrine, six patients had mainly or
only epinephrine production, and two patients showed
increase in ACTH. The clinical data are detailed in
Table 1. Histology of all tumors was reviewed to
confirm the diagnosis of PCC. None of the tumors had
adverse histopathological characteristics as published
by Thompson (2002), supporting the diagnosis of a
benign PCC in all cases. Tumor DNA was isolated
from fresh-frozen tumor tissue, except for four tumors
in which no frozen tissue was available and DNA was
isolated from paraffin-embedded archival material.
DNA from both fresh frozen and paraffin-embedded
material was isolated using the D-5000 Puregene
DNA Isolation kit (Gentra Systems, Minneapolis,
MN, USA) according to the manufacturers’
recommendations.
Array CGH labeling and hybridization
The submegabase tiling arrays (SMRT) previously
described by Ishkanian et al. (2004) were used,
consisting of 32 433 overlapping BAC clones. Test
DNA and pooled reference male DNA (Novagen,
Mississauga, ON, Canada; 300 ng each) were labeled
with cyanine-3 and cyanine-5 (PerkinElmer, Wood-
bridge, ON, Canada) respectively, according to a
random-priming protocol. After 18 h of random
priming, the reference and test DNA were combined
and 100 ml of Cot-1 DNA (Invitrogen) was added.
The mixture was purified using Microcon YM-30
columns (Millipore, Mississaga, ON, Canada). The
purified mixture was washed with 200 ml H2O, and
resuspended in 45 ml DIG easy hybridization solution
(Roche), containing 20 mg/ml sheared herring sperm
(Sigma-Aldrich) and 10 mg/ml yeast tRNA (Calbio-
chem, Mississauga, ON, Canada). The probe was
denatured at 85 8C for 10 min, followed by 60 min at
45 8C to block repetitive sequences, and subsequently
applied in a volume of 43 ml to the slide surface after
which coverslips were applied. The slides were
incubated at 45 8C for 36 h, washed four times for
5 min in 0.1! SSC, 0.1% SDS at room temperature,
and finally rinsed by 0.1! SSC for five times and dried
by centrifugation.
Array imaging and analysis
Hybridized slides were scanned using a charge-
coupled device camera system (Applied Precision,
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Issaquah, WA, USA), and analyzed by SoftWoRx
Tracker Spot Analysis software (Applied Precision).
Resultant data were normalized using a stepwise
normalization process (Khojasteh et al. 2005). Copy
number alterations were identified via data visuali-
zation using custom software called ‘SeeGH’ (freely
available at http://www.flintbox.ca/technology.
asp?techZFB312FB) and loss, normal, and gain
probabilities for each clone as determined by a
modified hidden Markov model (Chi et al. 2004,
Shah et al. 2006). Data were filtered based on both
replicate S.D. (data points with greater than 0.1 S.D.
removed) and signal-to-noise ratio (data points with a
signal-to-noise ratio !10 removed).
Mutation analysis
Mutation analysis was performed on a CGH profile
basis. Tumors showing loss of 1p were screened for
SDHBmutations (nZ26), those with loss of 3p for VHL
mutations (nZ11), and those with loss of 11q for SDHD
mutations (nZ10). Because no specific profile is
indicative of involvement of the RET proto-oncogene,
all 35 tumors were tested for RET mutations. All exons
including the intron–exon boundaries were screened,
with the exception of RET for which only exons 10, 11,
13, and 16 were investigated. PCR and sequencing
conditions have been previously described by Korper-
shoek et al. (2007). Corresponding normal DNA was
tested when an alteration was found in the tumor DNA.
Table 1 Clinical data
Patient
number m/f Age Location Diameter (cm) Weight (g)
Follow-up
(months) Hormone
1 m 43 A – 42 72 NE, E, D
2 m 65 A 18 458 60 NE, E, D
3 f 70 A 2.5 – 60 E
4 m 59 A 13 240 48 E, NE
5 m 63 A 5 67 3 E
6 f 40 A 7 180 9a NE
7 f 38 A 8 123 60 NE
8 m 29 A 12 710 37 –
10 f 25 EA 5 – 264 NE
11 m 24 A 2.5 – 72 NE, E
12 m 67 A 5.5 70 84 NE, E
13 m 24 A 6 66 4 E
14 m 46 A 7 246 4 NE
15 f 32 A 6 32 108 E
16 m 46 A 11.5 340 – –
17 f 65 A 6 49 – –
18 m 50 A 9 260 24 NE
19 m 56 A 16 – 12 –
20 m 43 A 7 79 – –
21 f 63 A 4 – – –
22 m 53 EA 9 193 24 NE
23 f 52 A 7 93 84 NE, E, D
24 f 24 A 3.5 – 36 NE, E, D
25 f 70 A 8.5 234 – E
26 f 70 A 6.5 137 – –
27 m 78 A 4.2 50 – –
28 m 41 A 7 – 2 NE, E, D
29 f 74 A 4 20 12 NE
30 m 29 A 7 – 60 ACTH
31 m 40 A 4.5 – – –
32 f 64 A 10 450 24 NE, E
33 m 9 A 4.8 – 18 –
34 f 48 A 8 – – –
36 f 26 A 7 – – ACTH
37 f 60 A 5 – 132 –
38 f 76 A 4 – – NE
A, adrenal; EA, extra-adrenal; NE, norepinephrine; E, epinephrine; D, dopamine; ACTH, adrenocorticotropic hormone. Bold italic
hormones are dominantly produced.
aDied, not related to PCC.
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Statistical analysis
Fisher’s exact test was applied, using SPSS version




All but two tumors included in this study yielded
interpretable array results. A frequency plot, adding
up percentages of loss and/or gain of each individual
BAC clone of all 34 analyzable tumors is shown in
Fig. 1. A representative karyogram of one tumor with
highlighted losses and polymorphisms is shown in
Fig. 2. Regions of previously reported natural copy
number variation were not included in the analysis of
these samples (Shah et al. 2006). The commonly
observed aberrations in each individual tumor sample
are summarized in Table 2. Interestingly, there were an
overwhelming number of copy number losses
compared with copy number gains. In addition, most
alterations encompassed whole chromosomes or
chromosome arms.
In general, loss of 1p was found in 76% (26/34) of
cases, where 88% (23/26) of these showed loss of the
entire p-arm. Three tumors showed regional loss,
consisting of 1p12–1p13.3, 1p31.3–1p36.33, and
1p12–1p35.1. Loss of 3q was observed in 59% (nZ20)
of the 34 tumors. No regional losses were observed.
Loss of 1p and additional 3q loss were shown to be
significantly associated (P!0.05).
Chromosome 3p loss was seen in 32% (nZ11) of the
tumors. In addition, eight of these tumors concordantly
showed loss of chromosome 11p. Chromosome 3p loss
was significantly associated with chromosome 11p loss
(P!0.05).
Loss of 11q was found in 29% (nZ10), with loss of
the whole arm in 80% of these (nZ8). The two tumors
that had a regional loss showed an overlap from
11q14.3 until the telomeric end of the q-arm. Loss of
chromosome 17p was found in 35% (nZ12), but no
regional losses were observed. Loss of 21q was
observed in 21% (nZ7), with one tumor showing a
regional loss of 21q22.11 until the telomere. Loss of
21q was shown to be significantly associated with loss
of 17p (P!0.05).
Finally, loss of chromosome 22 was found in 35%
(nZ12) with no regional losses. Interestingly, one
tumor displayed a high negative Log2Ratio, suggesting
more than just a single copy loss of that region of
the chromosome. However, with additional loss of
heterozygosity (LOH) analysis of several polymorphic
markers in that region, no homozygous deletion could
be identified (data not shown).
Because of the association between 1p and 3q
loss on one hand, and the association between 3p and
11p loss on the other hand, there appear to be two
distinct groups of PCC. The first group (nZ20)
encompassed tumors showing 1p and/or 3q loss,
1
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16 17 18 19 20 21 22
2 3 4 5 6 7 8
Figure 1 Frequency plot of all 38 PCC. Green lines on left side indicate loss of BAC clones situated in that area; red lines on right side
indicate gain. Blue bars on either side represent 25 and 50%.
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Figure 2 Karyogram of no. 28 showing the entire genome with magnified views of chromosomes 1, 3, 6, 8, 18, and 22. Each BAC
clone on the array is displayed as a point representing the segment of the genome covered. The shift of each data point to the left of 0
represents a loss of copy numbers, while a shift to the right represents a gain in copy numbers. The bars to the left and right of
CGH data represent Log2 ratios ofK0.5 and C0.5 respectively. To the right of the CGH data, hidden Markov model probabilities
are displayed. Probabilities range fromK1 (100% probability of copy number loss, green) toC1 (100% probability of copy
number gain, red). Well-known polymorphisms are evident throughout the genome and are apparent in the magnified views of
chromosomes 6 and 8.
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without having concurrent 3p loss. The second smaller
group (nZ11) showed loss of 3p with or without
concomitant loss of 11p. In addition, there was a
limited number of PCC (nZ3) that revealed no losses
of the previously mentioned chromosomal regions
(1p, 3p). One of these tumors showed gain of
chromosomes 15 and 20. The second tumor had loss
of the chromosomes 17 and 19, and gain of
chromosome 7. The third tumor showed loss
of chromosomes 11, 17, and 21.
Table 2 Loss of common regions
Patient
number 1p 3p 3q 11p 11q 17p 21q 22q
1 x x reg x x x
2 reg x
3 x x x
4 reg x x x x x
6 reg x x reg
7 x x
8 x x x x
10 x
12 x x x
13 x x x x
14 x x reg
16 x x x
17 x x x x
19 x x x x
20 x x x x
22 x x x x x
23 x x x x
25 x x x x
26 x x x
27 x x x
28 x x x
29 x x
30 x x
31 x x x x
32 x x x
15 x x x x
18 x x
24 x x x x
33 x x x x
34 x x x x
21 x
37 x x x x
x, loss; reg, regional loss (see text for locations).
Table 3 Mutation analysis results
Patient number Gene Mutation/cDNA Mutation/protein Hormone
28 RET c.1894_1899delGAGCTG p.E632_L633del NE, E, D
6 RET c.2332GO A p.V778I NE
12a RET c.2753TO C p.M918T NE, E
10 SDHB c.299CO T p.S100F NE
5 SDHB c.487CO T p.S163P E
29 SDHB c.487CO T p.S163P NE
23 SDHD c.149AO G p.H50R NE, E, D
20 VHL c.169_212delGGG_GCC p.G57LfsX60 –
15 VHL [c.364GO A; c.365CO T] p.A122I E
13 VHL c.482GO A p.R161Q E
34 VHL c.500GO A p.R167Q –
Mutations are in bold and polymorphism in italic. NE, norepinephrine; E, epinephrine; D, dopamine.
aIt is not known whether this mutation was germline or somatic. All other mutations were somatic.
F H van Nederveen et al.: Array-CGH in pheochromocytomas
www.endocrinology-journals.org510
Mutation analysis
Sequence analysis of the four PCC susceptibility genes
revealed mutations in seven tumors, of which three
occurred in RET, one in SDHB, and three in VHL
(Table 3). Analysis of corresponding germline DNA
confirmed that six of the mutations were somatic.
Corresponding germline DNA was not available from
patient 12 with the RET p.M918T mutation. With the
exception of the p.H50R polymorphism, no alterations
were found in SDHD. Furthermore, two additional
polymorphisms were found in SDHB which were both
p.S163P (Table 3).
The patients wit the RET mutations all had mainly
norepinephrine overproduction, of the four patients
with somatic VHL mutations only two had available
information on hormone production, both these tumors
showed only epinephrine overproduction.
Discussion
This study represents the first comprehensive analysis of
a large series of sporadic benign PCC using a genome-
wide submegabase-resolution tiling array (SMRT-
array). On the basis of DNA aberrations, we could
distinguish two distinct subgroups of PCC, one with loss
of 1p and/or 3q, representing more than 56% of all PCC
investigated, and a second, smaller, group with loss of
3p with or without concurrent 11p loss, representing
32% of these PCC. These findings may relate to the
different pathways of tumorigenesis in PCC.
The majority (76%) of PCC in this analysis of 36
benign sporadic tumors showed loss of 1p, which is
comparable with the frequency of loss that has been
reported in previous studies (Dannenberg et al. 2000,
Edstrom et al. 2000, Cascon et al. 2005). Moreover,
most PCC in our study (22/36) had loss of the entire
short arm of chromosome 1, by contrast to our previous
study, where we found regional 1p loss in half of
the cases (Aarts et al. 2006). We speculate that the
observed difference with our own previous studies and
with series from others is related to the composition of
the study group, which in the only present study
comprised sporadic cases. In the few cases with partial
loss, no minimal region of common loss could be
determined, preventing us to speculate on the presence
of one region harboring tumor suppressor genes on 1p,
which have been postulated by various authors (Geli
et al. 2005, Aarts et al. 2006). Still, based on the high
frequency of 1p loss in PCC, we support the idea of one
or more tumor suppressor genes on this chromosome
arm. In most cases, 1p loss was accompanied by loss
of 3q, which occurred in 62% of all cases with 1p loss,
a figure that is comparable with that reported in the
literature (Dannenberg et al. 2000, Edstrom et al. 2000,
Cascon et al. 2005). Four PCC were found with loss
of 3q without chromosome 1p loss. These four tumors
displayed loss of the entire chromosome three in
combination with loss of the entire chromosome 11
(see below).
Apart from the large group of PCC displaying a
1pK/3qK genotype, a smaller group of PCC was
identified with loss of 3p, which was frequently
accompanied by the loss of 11p. This pattern of loss
has been previously mentioned in PCC from VHL
patients, but has so far not been related to a subgroup
of sporadic PCC (Lui et al. 2002, Hering et al. 2006).
In order to exclude that this subgroup represented
occult VHL disease, we performed mutation analysis
of the entire VHL coding region, in which we could
not detect germline mutations. However, we found
three cases showing somatic VHL abnormalities.
The p.R161Q and p.A122I VHL mutations have been
described previously in an apparently sporadic PCC
(Neumann et al. 2002). The p.G57LfsX59 has never
been described before. Although, epigenetic silencing
of the VHL gene by hypermethylation is not
inconceivable, as seen in familial and non-familial
renal cell carcinoma, no methylation has been
described in PCC (Prowse et al. 1997). The fact that
a subgroup of sporadic PCC, without VHL germline
mutations, shows an identical genotype as VHL-related
PCC, leads to the suggestion that this group of PCC
follows similar pathways of tumorigenesis. Indeed,
this might also be the case for MEN2-related PCC
and the above-mentioned subgroup of sporadic PCC,
which have been shown to have similar frequencies of
1p and 3q loss in previous studies (Dannenberg et al.
2000, Edstrom et al. 2000, Cascon et al. 2005).
This is also supported by the hormone production in
these tumors, where the RET-related PCC showed
dominant norepinephrine production, and VHL-related
PCC showed only epinephrine production.
In addition to losses affecting chromosomes 1, 3, and
11, we observed the highest frequency of loss in
chromosomes 21 and 22, concerning 21 and 35% of all
PCC respectively. Loss of chromosome 21 has so far
not been described at this relatively high frequency in
benign sporadic PCC. All tumors with 22q loss
also displayed 1p loss, and all but one tumor with
chromosome 21q loss also revealed 1p loss. Therefore,
these regions could be involved in the spectrum of
the sporadic and/or MEN2-related PCC. However, as
there was only one tumor with regional loss of 21q,
we cannot draw conclusions with respect to the
presence of potential tumor suppressor genes on this
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chromosomal arm. Previous reports on the loss of
chromosome 22 have been based on LOH analysis and
showed loss of chromosomal bands 11.21–13.31, or
11.21 alone (Khosla et al. 1991, Tanaka et al. 1992,
Shin et al. 1993). Furthermore, in a recent array-CGH
study on 66 PCC, copy number alterations of 22q were
found in 44% (Khosla et al. 1991, Tanaka et al. 1992,
Shin et al. 1993). In eight of these cases (8/29), there
was regional loss with a minimal region of common
overlap from 22q11.23 until the telomeric end of
chromosome 22. One additional interstitial deletion
was found from 22q11.23 to 22q12.3. In our analysis,
we did not find a regional loss concerning chromosome
22q. These findings might indicate the presence of
tumor suppressor genes on 22q that could be involved
in the pathogenesis of sporadic PCC, however, due to
the large regions involved, combined with a gene-rich
chromosome it is not possible at this time to pinpoint
candidate genes.
Apart from the 31 PCC that could be fitted in either
of the two groups already mentioned, there were three
tumors that did not have losses in 1p, 3p or 3q. No
common pattern could be derived from these three
tumors, although it is interesting to note that two of
these presented with chromosomal gains. It is of
relevance to note that none of these were from an extra-
adrenal location, as these two PGL presented with a
CGH pattern that fitted well with that of the PCC.
Taken together, the predominant chromosomal
abnormalities found in this genome-wide array-CGH
study of 36 benign sporadic PCC concern losses of
various chromosomal arms, most notably 1p, 3p, 3q,
11p, 11q, 17p, 21q, and 22q. By contrast, we observed no
consistent gain of any chromosomal region. Further-
more, we could not confirm abnormalities of other
chromosomes that have been suggested in the literature,
such as aberrations of chromosomes 2 and 16 (Dahia
et al. 2005). In addition, there appear to exist two
different groups of benign sporadic PCC, each of them
characterized by a specific genotypic pattern of
chromosomal loss: a predominant form showing a 1p/
3q-genotype, which can also be found in MEN2-related
PCC; and a minor form showing a 3p-/11p-genotype,
which can also be found in VHL-related PCC. Apart
from this, the high frequency of loss of 21q and 22q
indicates that these chromosomal arms might also be
important in the pathogenesis of benign sporadic PCC.
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